Continuous low-dose cyclophosphamide (NSC-26271) therapy in advanced ovarian cancer

Costantino Mangioni, Giorgio Bolis, Nicola Natale, Luciano Morasca

Research output: Contribution to journalArticlepeer-review


A low dose, continuous treatment by cyclophosphamide (100 mg/day p.o.) has been given to 141 patients with documented Müllerian ovarian cancer. From this total 134 have been evaluated for drug related toxicity. Response and survival have been studied in 72 patients in stages III, IV or in recurrence, all with at least one measurable tumor mass. Results demonstrate that this regimen of administration induces remission and prolongation of median survival with a very low level of toxicity and minimal discomfort to the patient.

Original languageEnglish
Pages (from-to)353-356
Number of pages4
JournalEuropean Journal of Cancer (1965)
Issue number5
Publication statusPublished - 1976

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Continuous low-dose cyclophosphamide (NSC-26271) therapy in advanced ovarian cancer'. Together they form a unique fingerprint.

Cite this